TSE:GEN GeneNews (GEN) Stock Price, News & Analysis Add Compare Share Share Today's Range N/A50-Day RangeC$0.15▼C$0.1552-Week Range N/AVolume473,147 shsAverage Volume1.48 million shsMarket CapitalizationC$25.49 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get GeneNews alerts: Email Address Ad Paradigm PressMan who Predicted Trump 2016 Win: “Prepare for Election Meltdown”Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… A predicted Trump would win. You won’t believe what he’s predicting now.Click here to see it because it’s a SHOCKER… About GeneNews Stock (TSE:GEN)GeneNews Limited focuses on developing and commercializing proprietary molecular diagnostic tests for the early detection of diseases and personalized health management with a primary focus on cancer-related indications. Its proprietary platform technology, the Sentinel Principle, identifies novel biomarkers from whole blood. The company's lead product is ColonSentry, a blood test to determine an individual's current risk for having colorectal cancer. GeneNews Limited was founded in 1998 and is headquartered in Richmond Hill, Canada.Read More Ad Paradigm PressMan who Predicted Trump 2016 Win: “Prepare for Election Meltdown”Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… A predicted Trump would win. You won’t believe what he’s predicting now.Click here to see it because it’s a SHOCKER… GEN Stock News HeadlinesMay 16, 2024 | washingtonpost.comGeneNews: Q1 Earnings SnapshotJanuary 18, 2024 | msn.comVertex, Crispr Get Second FDA Approval for Gene TherapyJuly 26, 2024 | Porter & Company (Ad)We recommended Nvidia in 2016, now we’re recommending this…The AI boom is just getting started. And the real wealth has still to be made…January 17, 2024 | msn.comGene-editing treatment from Vertex and CRISPR cleared for second rare blood disorderJanuary 17, 2024 | msn.comFDA expands use of newly approved CRISPR therapyJanuary 16, 2024 | washingtonpost.comOhio St hires Texas A&M athletic director Ross Bjork to replace the retiring Gene SmithNovember 27, 2023 | msn.comMutated gene thought to exist in just 4% of people could ‘help tackle obesity’November 18, 2023 | nytimes.comSickle-Cell Treatment Created With Gene Editing Wins U.K. ApprovalJuly 26, 2024 | Porter & Company (Ad)We recommended Nvidia in 2016, now we’re recommending this…The AI boom is just getting started. And the real wealth has still to be made…November 17, 2023 | msn.comUK authorizes gene therapy for blood disorders in world firstNovember 16, 2023 | msn.comMac Jones Losing Support of Patriots Teammates After Being Benched for Third Time, ReportNovember 16, 2023 | usatoday.comGene Frenette: Mac Jones' decline with Patriots also a product of Bill Belichick negligenceOctober 31, 2023 | msn.comSarepta Seeks Broader Approval for Gene Therapy Even After Drug Trial FizzledOctober 31, 2023 | wsj.comSarepta Therapeutics Stock Dives After New Gene Therapy DataOctober 31, 2023 | msn.comFDA panel considers gene therapy as a potential cure for the sickest sickle cell patientsMarch 27, 2023 | marketwatch.comOncology Molecular Diagnostics Market by 2031March 19, 2023 | marketwatch.comGlobal Colorectal Cancer Diagnostic Market Industry Insights, Drivers, Top Trends, Global Analysis, Forecast and Opportunities to 2030 By VMReportsJanuary 5, 2023 | thestreet.comBiotech Stock Mailbag: GenVecSee More Headlines Receive GEN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for GeneNews and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeTSE SectorMedical Industry Diagnostics & Research Sub-IndustryComputer Software Current SymbolTSE:GEN CUSIPN/A CIKN/A Webwww.genenews.com Phone+1-905-7392030FaxN/AEmployees2,700Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio0.10 Quick Ratio0.05 Sales & Book Value Annual SalesC$234,592.00 Price / Sales0.00 Cash FlowN/A Price / Cash Flow145.00 Book ValueC($0.06) per share Price / BookN/AMiscellaneous Outstanding Shares169,963,000Free FloatN/AMarket CapC$25.49 million OptionableNot Optionable BetaN/A 20 High-Yield Dividend Stocks that Could Ruin Your RetirementAlmost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.Get This Free Report Key ExecutivesMr. James R. Howard-TrippExec. Chairman & CEOMs. Joanna M. Halsey Esq.Gen. Counsel, Chief Compliance Officer & HR Director of IDLProf. Choong-Chin Liew Ph.D.Co-FounderMr. Warren Whitehead (Age 67)Chief Accountant Mr. David SuriaSr. ScientistKey CompetitorsSherritt InternationalTSE:SReliq Health TechnologiesCVE:RHTMeta GrowthCVE:METADevonian Health GroupCVE:GSDRocky Mountain LiquorCVE:RUMView All Competitors GEN Stock Analysis - Frequently Asked Questions How do I buy shares of GeneNews? Shares of GEN stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.Compare Top Brokerages Here. What other stocks do shareholders of GeneNews own? Based on aggregate information from My MarketBeat watchlists, some other companies that GeneNews investors own include StorageVault Canada (SVI), American Airlines Group (AAL), Aareal Bank (ARL), Broadcom (AVGO) and Aspen Technology (AZPN). This page (TSE:GEN) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredCollapse of the PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...Colonial Metals | SponsoredFormer Hedge Fund Manager Issues Crash PredictionOur No. 1 stock for the rare "millionaire window" opening NOW According to Wall Street legend Whitney Tilso...Stansberry Research | SponsoredBrace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding GeneNews Ltd Please log in to your account or sign up in order to add this asset to your watchlist. Share GeneNews With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.